HYUNDAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,750 KRW | -1.06% |
|
-0.92% | -8.76% |
| 2023 | Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023. | CI |
| 2023 | Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index | CI |
| Sales 2012 | 102B 74.44M | Sales 2013 | 108B 78.72M | Capitalization | 42.44B 30.9M |
|---|---|---|---|---|---|
| Net income 2012 | -4.85B -3.53M | Net income 2013 | 1.42B 1.03M | EV / Sales 2012 | 0.48 x |
| Net Debt 2012 | 12.68B 9.23M | Net Debt 2013 | 6.12B 4.46M | EV / Sales 2013 | 0.45 x |
| P/E ratio 2012 |
-7.47
x | P/E ratio 2013 |
30
x | Employees | 393 |
| Yield 2012 |
2.39% | Yield 2013 |
2.32% | Free-Float | 58.96% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.06% | ||
| 1 week | -0.92% | ||
| Current month | -3.10% | ||
| 1 month | -2.60% | ||
| 3 months | -2.47% | ||
| 6 months | +1.08% | ||
| Current year | -8.76% |
1 week
3 700.00
3 800.00
1 month
3 700.004 055.00
Current year
3 700.004 280.00
1 year
3 510.005 530.00
3 years
3 510.008 500.00
5 years
2 800.0011 000.00
10 years
2 045.0011 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Joon Lee
CEO | Chief Executive Officer | 47 | 03-02-27 |
Seok-Bong Lee
DFI | Director of Finance/CFO | 67 | 89-05-07 |
Young-Hak Kim
BRD | Director/Board Member | 62 | 07-10-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Han-Gu Lee
CHM | Chairman | 76 | 74-08-08 |
Cheon-Soo Ham
BRD | Director/Board Member | 77 | 99-02-04 |
Sang-Joon Lee
CEO | Chief Executive Officer | 47 | 03-02-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3,750 | -1.06% | 40,040 |
| 24-04-18 | 3,790 | +1.20% | 29,941 |
| 24-04-17 | 3,745 | +1.08% | 32,374 |
| 24-04-16 | 3,705 | -1.98% | 82,296 |
| 24-04-15 | 3,780 | -0.13% | 39,912 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
Sector
Pharmaceuticals
Calendar
2024-07-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.76% | 75.45M | |
| +20.91% | 43.82B | |
| +16.96% | 21.73B | |
| +9.05% | 13.95B | |
| +7.98% | 13.03B | |
| +33.80% | 11.13B | |
| -11.05% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.64% | 5.05B |
- Stock Market
- Equities
- A004310 Stock
